Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Danazol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 3/20 | 1.00 |
| ▸ | AR known ✓ | P10275 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | ESR1 | P03372 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Danazol SCHEMBL14045163 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL5021653 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL21107 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL5499397 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL13184574 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL23468175 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL5248054 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL27720831 | 0.96 | CYP3A4 (0.93) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL4780325 | 0.93 | LMNA (0.86) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL3146698 | 0.89 | CYP3A4 (0.80) | CYP3A4LMNATSHRCYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987292-B2 | Method for treatment of diseases | AMPIO PHARMACEUTICALS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987292-B2 | Method for treatment of diseases | AMPIO PHARMACEUTICALS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160256475-A1 | METHODS OF TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160256475-A1 | METHODS OF TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160175326-A1 | METHOD FOR TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160175326-A1 | METHOD FOR TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160158250-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160158250-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9351979-B2 | Methods of treatment of diseases | AMPIO PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351979-B2 | Methods of treatment of diseases | AMPIO PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20130005699-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI ACQUISITION CORP. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8227457-B2 | Method for treatment of diseases | DMI ACQUISITION CORP. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120077789-A1 | METHOD FOR TREATMENT OF DISEASES | DMI ACQUISITION CORP. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120035147-A1 | METHOD FOR TREATMENT OF DISEASES | DMI ACQUISITION CORP. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110171307-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110171306-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| WO-2010151531-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI ACQUISTION CORP. (US) | 2010-12-29 | — | — | WO | disclosed |
| US-20100324005-A1 | METHOD FOR TREATMENT OF DISEASES | DMI ACQUISITION CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100323991-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI ACQUISITION CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20070111972-A1 | \"METHODS AND PRODUCTS FOR TREATMENT OF DISEASES\ | DMI BIOSCIENCES, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035147-A1 | METHOD FOR TREATMENT OF DISEASES | DIAPH1, MYLK, ROCK2 | PGR 4601/4885AR 4862/4885CYP3A4 4430/4885 |
| US-20160158250-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | MYLK, ROCK1, ROCK2 | PGR 4447/4885AR 4749/4885CYP3A4 3732/4885 |
| US-20160256475-A1 | METHODS OF TREATMENT OF DISEASES | PLIN5, MYLK, PLIN3 | PGR 4582/4885AR 4692/4885CYP3A4 3793/4885 |
| US-20110171306-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | VEGFA, PGF, BDNF | PGR 239/4885AR 1551/4885CYP3A4 2417/4885 |
| US-20070111972-A1 | \"METHODS AND PRODUCTS FOR TREATMENT OF DISEASES\ | PGF, VEGFA, BDNF | PGR 350/4885AR 2029/4885CYP3A4 2070/4885 |
| US-20120077789-A1 | METHOD FOR TREATMENT OF DISEASES | DIAPH1, MYLK, ROCK2 | PGR 4601/4885AR 4862/4885CYP3A4 4430/4885 |
| US-20130005699-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | MYLK, ROCK1, ROCK2 | PGR 4447/4885AR 4749/4885CYP3A4 3732/4885 |
| US-20100324005-A1 | METHOD FOR TREATMENT OF DISEASES | DIAPH1, MYLK, ROCK2 | PGR 4601/4885AR 4862/4885CYP3A4 4430/4885 |
| US-20100323991-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | MYLK, ROCK1, ROCK2 | PGR 4447/4885AR 4749/4885CYP3A4 3732/4885 |
| US-20160175326-A1 | METHOD FOR TREATMENT OF DISEASES | DIAPH1, MYLK, ROCK2 | PGR 4601/4885AR 4862/4885CYP3A4 4430/4885 |
| US-20110171307-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | VEGFA, PGF, BDNF | PGR 239/4885AR 1551/4885CYP3A4 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.